# Phase 1/2 prostatic cancer trials recruiting: 94 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 94 trials in phase 1/2 for prostatic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 prostatic cancer trials: 94 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/prostatic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 94
- Recruiting or not yet: 94
- Read on: November 19, 2026

## Trials

The 25 newest of 94, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07945821 | A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors | Coherus Oncology, Inc. | Phase 1/2 | Recruiting | Solid Tumor | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945821) |
| November 4, 2026 | NCT07917390 | ALT-100 Monoclonal Antibody (mAb) in Bone-Predominant Metastatic Androgen Pathway Modulation Resistant (APMR) Prostate Cancer -- The... | University of Florida | Phase 1/2 | Not yet recruiting | Prostate Cancer Metastatic to Bone | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917390) |
| October 29, 2026 | NCT07902921 | STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic... | National Cancer Institute (NCI) | Phase 1/2 | Not yet recruiting | NSCLC, Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer, Thymic Epithelial Tumors, TETs, Thymic Carcinomas... | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902921) |
| October 7, 2026 | NCT07862582 | RYZ711 Diagnostic Platform Study | RayzeBio, Inc. | Phase 1/2 | Recruiting | Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer... | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862582) |
| September 30, 2026 | NCT07850921 | REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Metastatic Castration-Resistant Prostate Cancer, mCRPC | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850921) |
| September 1, 2026 | NCT07796490 | Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer | The Methodist Hospital Research Institute | Phase 1/2 | Not yet recruiting | Prostate Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796490) |
| August 14, 2026 | NCT07765940 | Safety and Preliminary Diagnostic Performance of \[⁶⁴Cu\]Cu-RAX301 in Prostate Cancer | RadAlliance Therapeutics, Inc | Phase 1/2 | Not yet recruiting | Prostate Cancer | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765940) |
| July 28, 2026 | NCT07730125 | Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | CoRegen, Inc. | Phase 1/2 | Not yet recruiting | HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730125) |
| July 15, 2026 | NCT07705074 | FAPI PET Imaging - An Exploratory Study | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis, Thyroid Cancer, Breast Cancer... | 770 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705074) |
| July 8, 2026 | NCT07689656 | A Clinical Study of \[68Ga\]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1/2 | Recruiting | Prostate Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689656) |
| June 25, 2026 | NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | University of Nebraska | Phase 1/2 | Not yet recruiting | Prostate Cancer, Uterine Cancer, Cervical Cancer, Anal Cancer | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668284) |
| June 25, 2026 | NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667400) |
| May 15, 2026 | NCT07590934 | Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer | AstraZeneca | Phase 1/2 | Recruiting | Metastatic Prostate Cancer | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07590934) |
| May 5, 2026 | NCT07567846 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate... | Genentech, Inc. | Phase 1/2 | Recruiting | Advanced Prostate Cancer, Metastatic Prostate Cancer | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07567846) |
| May 5, 2026 | NCT07567521 | A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC | C Ray Therapeutics | Phase 1/2 | Recruiting | Prostate Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07567521) |
| May 4, 2026 | NCT07564102 | dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy | Mochida Medical USA, Inc. | Phase 1/2 | Not yet recruiting | Prostate Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07564102) |
| April 14, 2026 | NCT07529717 | First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer | AstraZeneca | Phase 1/2 | Recruiting | Metastatic Prostate Cancer | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529717) |
| April 13, 2026 | NCT07523529 | Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Unresectable, Metastatic | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523529) |
| March 2, 2026 | NCT07441889 | HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006) | University of Virginia | Phase 1/2 | Recruiting | Breast Cancer, Prostate Cancer | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441889) |
| February 17, 2026 | NCT07414940 | ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium | University College, London | Phase 1/2 | Recruiting | Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07414940) |
| February 13, 2026 | NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer... | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410676) |
| February 13, 2026 | NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic), Prostate... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410494) |
| February 12, 2026 | NCT07407283 | A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 1/2 | Recruiting | Prostate Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407283) |
| January 23, 2026 | NCT07363486 | Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | First Affiliated Hospital of Fujian Medical University | Phase 1/2 | Recruiting | Prostate Cancer | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07363486) |
| January 23, 2026 | NCT07363382 | The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer | First Affiliated Hospital of Fujian Medical University | Phase 1/2 | Recruiting | Prostate Cancer (Adenocarcinoma) | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07363382) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 6 |
| M.D. Anderson Cancer Center | 3 |
| First Affiliated Hospital of Fujian Medical University | 3 |
| The Methodist Hospital Research Institute | 3 |
| National Cancer Institute (NCI) | 3 |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 3 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 2 |
| Essen Biotech | 2 |
| SpectraCure AB | 2 |
| University of Florida | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| Mochida Medical USA, Inc. | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| CHU de Quebec-Universite Laval | 1 |
| C Ray Therapeutics | 1 |
| University of Michigan Rogel Cancer Center | 1 |
| Parabilis Medicines, Inc. | 1 |
| University College, London | 1 |
| Kidney Cancer Research Bureau | 1 |
| Twinpig Biolab, Inc. | 1 |
| Filamon LTD | 1 |
| MBrace Therapeutics | 1 |
| Washington University School of Medicine | 1 |
| Clarity Pharmaceuticals Ltd | 1 |
| PMV Pharmaceuticals, Inc | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 57 |
| China | 21 |
| Australia | 16 |
| United Kingdom | 15 |
| Spain | 14 |
| France | 9 |
| South Korea | 9 |
| Canada | 7 |
| Germany | 7 |
| Japan | 6 |
| Italy | 6 |
| Netherlands | 5 |
| Belgium | 3 |
| Switzerland | 3 |
| Poland | 3 |
| Taiwan | 3 |
| Singapore | 2 |
| Sweden | 2 |
| Brazil | 2 |
| Russia | 1 |
| Egypt | 1 |
| Argentina | 1 |
| Chile | 1 |
| Ireland | 1 |
| Israel | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Graphic design firms in the United States](https://specstream.ai/data/businesses/graphic-design-firms/united-states)
- [Audiology clinics in the United States](https://specstream.ai/data/businesses/audiology-clinics/united-states)
- [Packing supply stores in the United States](https://specstream.ai/data/businesses/packing-supply-stores/united-states)
- [Doner kebab restaurants in the United States](https://specstream.ai/data/businesses/doner-kebab-restaurants/united-states)
- [Tower communication companies in the United States](https://specstream.ai/data/businesses/tower-communication-companies/united-states)
- [Janitorial companies in the United States](https://specstream.ai/data/businesses/janitorial-companies/united-states)
